Dianthus Therapeutics, Inc. (DNTH)
After hours:
| Previous close | 20.70 |
| Open | 20.71 |
| Bid | 21.45 x 400 |
| Ask | 21.90 x 100 |
| Day's range | 20.62 - 21.92 |
| 52-week range | 0.62 - 33.77 |
| Volume | |
| Avg. volume | 152,942 |
| Market cap | 634.243M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.71 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 49.29 |
GlobeNewswireDianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York. A live webcast of this presen
Simply Wall St.Companies Like Dianthus Therapeutics (NASDAQ:DNTH) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor Neuropathy (MMN) to initiate 2Q’24 and Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to initiate 2H’24 $377 million of cash, including proceeds from a successful $230 million PIPE financing completed in January 2024, provides runway into 2H 2027 NEW YORK and WALTHAM, Mass., May
